GS
KRON

Gilead Sciences’s Kronos Bio KRON Stock Holding History

Gilead Sciences’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-188,567
Closed -$179K – 16
2024
Q4 		$179K Buy
+188,567
New +$178K 0.01% 16

Other funds holding KRON

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.83B AUM 20.31% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Gilead Sciences's KRON Position: Q1 2025 in Review

Gilead Sciences sold out of Kronos Bio (KRON) in Q1 2025, closing a stake of 188,567 shares — an estimated $179K sold.

Gilead Sciences first reported a position in KRON in Q4 2024 and held it in 1 quarter. The position peaked at $179K in Q4 2024. 47 funds tracked by Wall St. Rank hold KRON as of Q1 2025.

  • Gilead Sciences reported no remaining Kronos Bio position as of Q1 2025 after selling out during the quarter.
  • Gilead Sciences sold 188,567 Kronos Bio shares in Q1 2025, an estimated $179K.
  • Gilead Sciences first reported a position in Kronos Bio in Q4 2024 and held it in 1 quarter.
  • Gilead Sciences's Kronos Bio position peaked at $179K in Q4 2024.
  • 47 funds tracked by Wall St. Rank held Kronos Bio as of Q1 2025.

Based on Gilead Sciences's 13F filing for Q1 2025, filed 13 May 2025.